文献速递脊柱关节炎

银屑病关节炎中无改善病情抗风湿药缓解:是否可及且可持续?一项大型纵向研究

Disease-modifying antirheumatic drug-free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study.
PubMed 文献 · Ann Rheum Dis · 2025-05-16

在荷兰西南部早期银屑病关节炎队列的451例新诊断寡关节/多关节型患者中,22%达到无改善病情抗风湿药缓解(DFR),14.4%达到持续DFR,9.1%达到无复发的真性持续DFR。基线银屑病关节炎疾病活动指数低和从未使用生物或靶向合成改善病情抗风湿药是真性持续DFR的独立预测因素。

要点

  • 中位5.1年后22%的银屑病关节炎患者达到无改善病情抗风湿药缓解,9.1%达到无复发的真性持续缓解。
  • 达到无改善病情抗风湿药缓解后4.7%出现早期复发,5.3%出现晚期复发(中位1.7年后)。
  • 基线疾病活动指数低和从未使用生物/靶向合成改善病情抗风湿药是真性持续缓解的独立预测因素。

核心结论

  • 无改善病情抗风湿药缓解在寡关节/多关节型银屑病关节炎中可达到,并在9%的患者中可持续。
  • 基线高疾病活动且需要生物或靶向合成改善病情抗风湿药的患者亚组未达到真性持续无改善病情抗风湿药缓解。
  • 据作者所知,这是首个表明部分银屑病关节炎患者的慢性病程可能受到影响的 seated 研究。

研究设计与样本

  • 来自荷兰西南部早期银屑病关节炎队列,纳入所有接受改善病情抗风湿药治疗的新诊断寡关节/多关节型银屑病关节炎患者(n=451)。
  • 描述(持续)无改善病情抗风湿药缓解的患病率和复发率(早期和晚期),并探索真性持续无改善病情抗风湿药缓解的预测因素。

主要发现

  • 中位5.1年(IQR 3.0-7.3年)后,22%的银屑病关节炎患者达到无改善病情抗风湿药缓解。
  • 达到无改善病情抗风湿药缓解后,4.7%出现早期复发;14.4%达到持续无改善病情抗风湿药缓解。
  • 5.3%出现晚期复发,发生于停用改善病情抗风湿药后中位1.7年(IQR 1.4-2.8年);最终9.1%达到真性持续无改善病情抗风湿药缓解。
  • 基线银屑病关节炎疾病活动指数低和从未使用生物或靶向合成改善病情抗风湿药是真性持续无改善病情抗风湿药缓解的独立预测因素。
  • 达到真性持续无改善病情抗风湿药缓解时,健康评估问卷与一般人群相似(中位0.12;IQR 0-0.75)。

关键数值与推荐

  • 无改善病情抗风湿药缓解定义为停用改善病情抗风湿药后无临床滑膜炎≥3个月。
  • 持续无改善病情抗风湿药缓解定义为停用改善病情抗风湿药后无临床滑膜炎>1年。
  • 早期复发定义为停用改善病情抗风湿药后≤1年重新开始改善病情抗风湿药治疗;晚期复发定义为停用改善病情抗风湿药后>1年重新开始改善病情抗风湿药治疗。

临床怎么用

  • 现行管理指南认为银屑病关节炎可考虑改善病情抗风湿药减量。
  • 原文未据此给出关于完全停用改善病情抗风湿药的推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: According to current management guidelines for psoriatic arthritis (PsA) tapering of disease-modifying antirheumatic drugs (DMARDs) can be considered. However, limited data are available on complete DMARD cessation, also known as disease-modifying antirheumatic drug-free remission (DFR). Therefore, our aim was to investigate whether DFR is achievable and sustainable in PsA and to evaluate possible predictors for sustained disease-modifying antirheumatic drug-free remission (SDFR). METHODS: From the Dutch southwest Early Psoriatic Arthritis cohort, all newly diagnosed patients with oligoarticular/polyarticular PsA who were treated with DMARDs were included (n = 451). Prevalence of (S)DFR and flare rates (early and late) were described. DFR was defined as the absence of clinical synovitis for ≥3 months after DMARD cessation, while for SDFR, a period of >1 year was used. Early and late flares were defined as restarting DMARD treatment ≤1 and >1 year after DMARD cessation, respectively. Subsequently, possible predictors for true SDFR, that is, SDFR without flaring were explored. RESULTS: After a median of 5.1 years (IQR, 3.0-7.3 years), 22% of patients with PsA had reached DFR, and after reaching DFR, 4.7% had an early flare. Thus, SDFR was achieved in 14.4% of patients with PsA; 5.3% experienced a late flare, which occurred a median of 1.7 years (IQR, 1.4-2.8 years) after DMARD cessation. Eventually, 9.1% of patients reached true SDFR. Low baseline Disease Activity Index in Psoriatic Arthritis and never using biological or targeted synthetic DMARDs were independent predictors for true SDFR. At the time of true SDFR, the Health Assessment Questionnaire was similar to the general population (median, 0.12; IQR, 0-0.75). CONCLUSIONS: DFR is attainable in oligoarticular/polyarticular PsA and is sustainable in 9% of patients. However, the subgroup of patients with PsA with high disease activity at baseline and who require biological or targeted synthetic DMARDs do not achieve true SDFR. To our knowledge, this is the first study to demonstrate that chronicity can potentially be influenced in a proportion of patients with PsA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Snoeck Henkemans SVJ, Vis M, Koc GH, et al. Disease-modifying antirheumatic drug-free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study. Ann Rheum Dis. 2025. PMID: 40382308. doi:10.1016/j.ard.2025.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。